Lilly, market launching of Strattera for ADHD treatment.

Published: 2007-06-29 06:57:00

Updated: 2007-06-29 06:57:00

Lilly Korea announced market launching of Strattera (atomoxetine), an ADHD therapeutic drug, having 24 hour sustained activity by once a day administration.

Strattera (atomoxetine), a new non-stimulant drug to treat ADHD in adults and children over age 6 is a selective norepinephrine reuptake...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK